Research on Anti-diabetic activity of Syzygium cumini and its isolated compound against streptozotocin- induced diabetic rats

Abstract

Syzygium cumini (Myrtaceae) is widely used traditional system of medicine to treat diabetes in India. The present study was carried out to isolate and identify the putative antidiabetic compound from the S. cumini [SC] seed. A compound, mycaminose was isolated from SC seed extract. The isolated compound mycaminose (50 mg/kg) and ethyl acetate [EA] and methanol [ME] extracted compounds of S. cumini seed (200 and 400 mg/kg) was undertaken to evaluate the anti-diabetic activity against streptozotocin (STZ)-induced diabetic rates. The compound ‘Mycaminose’ and ethyl acetate and methanol extracted produced significant (p<0.05) reduction in blood glucose level. The standard drug, glibenclamide (1.25 mg/kg) also produced significant (p<0.05) reduction in blood glucose level against STZ-induced diabetic rats. The results of this experimental study indicate that isolated compound ‘Mycaminose’, ethyl acetate and methanol extracts possess anti-diabetic effects against STZ-induced diabetic rats.